-Neurocrine Biosciences, Inc. announced the FDA has accepted its New Drug Application (NDA) for Ingrezza (valbenazine) oral granules, a new sprinkle formulation of Ingrezza (valbenazine) capsules for oral administration. The agency set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024
TD is characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face.
Neurocrine Biosciences, Inc. announced that the FDA has approved Ingrezza (valbenazine) capsules for the treatment of adults with tardive dyskinesia...
Neurocrine Biosciences announced new data from RE-KINECT, the largest real-world screening study to date of patients using Ingrezza (valbenazine) with...
Neurocrine Biosciences, Inc. announced the FDA has approved Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD).
Neurocrine Biosciences announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg dose of Ingrezza (valbenazine)...
Neurocrine Biosciences, Inc. announced interim results from the ongoing open-label KINECT -HD2 study about Ingrezza (valbenazine) capsules when used for the long-term treatment of adults with chorea associated with Huntington's disease (HD)